Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

A Quon; S. T Chang; F Chin; A Kamaya; D. W Dick; B. W Loo; S. S Gambhir; A. C Koong

doi:10.1007/s00259-007-0630-z

Back

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Journal article

Open access

Peer reviewed

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

A Quon, S. T Chang, F Chin, A Kamaya, D. W Dick, B. W Loo, S. S Gambhir and A. C Koong

European journal of nuclear medicine and molecular imaging, Vol.35(3), pp.527-531

03/2008

DOI: 10.1007/s00259-007-0630-z

PMCID: PMC4144989

PMID: 17960376

Files and links (1)

url

http://doi.org/10.1007/s00259-007-0630-zView

Open Access

Abstract

Purpose The aim of this study was to evaluate the potential of 18F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, 18F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses. Results The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%). Conclusions In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

Oncology

Pancreatic Cancer

FLT PET

FDG PET

PET

Details

Title: Subtitle: Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer
Creators: A Quon - Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305, USA
S. T Chang - Department of Radiation Oncology, Stanford University Medical Center, 268 Campus Drive, Room 1245, Stanford, CA, USA
F Chin - Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305, USA
A Kamaya - Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305, USA
D. W Dick - Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305, USA
B. W Loo - Department of Radiation Oncology, Stanford University Medical Center, 268 Campus Drive, Room 1245, Stanford, CA, USA
S. S Gambhir - Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305, USA
A. C Koong - Department of Radiation Oncology, Stanford University Medical Center, 268 Campus Drive, Room 1245, Stanford, CA, USA
Resource Type: Journal article
Publication Details: European journal of nuclear medicine and molecular imaging, Vol.35(3), pp.527-531
DOI: 10.1007/s00259-007-0630-z
PMID: 17960376
PMCID: PMC4144989
NLM abbreviation: Eur J Nucl Med Mol Imaging
ISSN: 1619-7070
eISSN: 1619-7089
Language: English
Date published: 03/2008
Academic Unit: Radiology; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984051993802771

Metrics

16 Record Views

34 Times Cited - Web of Science